Latest News

Overview of long-term data in RRMS

 

The following summarizes the long-term treatment data presented at ECTRIMS 2018.

Teriflunomide: The long-term (up to 12.5 years) efficacy and safety of teriflunomide were examined in a pooled analysis of phase II and phase III trials and their extensions (Freedman et al. ECTRIMS 2018; abstract P1233); cumulative drug exposure was 1357 patient-years. The annualized relapse for patients treated with teriflunomide 14 mg was 0.38 vs. 0.59 with placebo. The proportion of patients with serious adverse events and the proportion discontinuing due to adverse events was comparable with teriflunomide and placebo (12.4% vs. 12.8%; and 6.9% vs. 13.1%, respectively). Read More

Oral cladribine recommended for public reimbursement in Canada

 

The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that oral cladribine (Mavenclad) be reimbursed by provincial drug plans for the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients who are eligible for oral cladribine are those with an inadequate response or poor tolerability with one prior disease-modifying therapy (DMT), and who have had at least one relapse within the previous 12 months. Read More

TOPICS:

ECTRIMS 2018 Poster Gallery

 

2018 European Committee for Treatment and Research in Multiple Sclerosis meeting (ECTRIMS) annual meeting, Berlin, Germany, October 10-12, 2018

Selected posters presented by researchers at ECTRIMS 2018. Read More